Cubist Systematic Strategies, LLC Vaxcyte, Inc. Transaction History

Cubist Systematic Strategies, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $4.31 Million - $5.61 Million	-118,812 Reduced 79.68%	30,308 $1.14 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $2.43 Million - $5.65 Million	117,905 Added 377.72%	149,120 $7.15 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $428,420 - $563,524	19,752 Added 172.31%	31,215 $749,000
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $202,665 - $304,686	11,463 New	11,463 $249,000
Q1 2021 May 17, 2021	SELL	$18.66 - $29.16 $182,270 - $284,834	-9,768 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$26.57 - $51.74 $259,535 - $505,396	9,768 New	9,768 $260,000

357

123M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.26B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.